Control group Cpk Cpa   χ2 p OR 95%CI
ERCC4rs3136176 / ERCC4rs1799798
A A 45.89 (0.111) 13.00 (0.197) 23.99 (0.133) Cpkvs.Cpa
Cpkvs. Control group
Cpavs. Control group
1.534
3.854
0.575
0.215556
0.049650
0.448350
0.627
1.956
1.226
0.2981.319
0.991 – 3.861
0.7232.080
A G 267.11 (0.645) 37.00 (0.561) 102.01 (0.567) Cpkvs.Cpa
Cpkvs. Control group
Cpavs. Control group
0.007
1.899
3.564
0.931129
0.168200
0.059054
1.025
0.692
0.709
0.5811.810
0.408 – 1.171
0.496 – 1.014
T G 98.89 (0.239) 16.00 (0.242) 53.99 (0.300) Cpkvs.Cpa
Cpkvs. Control group
Cpavs. Control group
0.785
0.002
2.343
0.375562
0.967137
0.125836
1.339
1.013
1.356
0.7012.557
0.552 – 1.858
0.917 – 2.005
T A 2.11 (0.005) 0.00 (0.000) 0.01 (0.000) Cpkvs.Cpa
Cpkvs. Control group
Cpavs. Control group








Total control group= 414.0, total Cpk= 66.0, total Cpa=180.0
Cpkvs.Cpa: χ2Global= 1.868017, df= 2 (frequency <0.03 in both Cpk&Cpa has been dropped), p= 0.392975
Cpk vs. control group: χ2Global= 4.070642, df= 2 (frequency <0.03 in both Cpk& control group has been dropped), p= 0.130639
Cpa vs. control group: χ2Global= 3.586152, df= 2 (frequency <0.03 in both Cpa& control group has been dropped), p= 0.166447
Table 6: ERCC4rs3136176 and ERCC4rs1799798 haplotype in cervical squamous cell carcinoma (CSCC): carcinoma planoepitheliale keratodes (Cpk), and carcinoma planoepitheliale aceratodes (Cpa) and healthy women.